The global lung cancer surgery market is projected to reach USD 6.7 billion by 2026 from USD 5.4 billion in 2020, at a CAGR of 3.8% during the forecast period. Market growth is largely driven by factors such as the technological advancements in lung cancer treatment, increasing incidence and prevalence of lung cancer, growing trend of smoking tobacco, rising geriatric population, increasing emphasis on early diagnosis & treatment of cancers, and availability of reimbursement. However, the high cost of lung cancer diagnosis & surgery is expected to restrain the growth of this market during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=222

COVID-19 Impact on Global Lung cancer surgery market


COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 moved from a regional crisis to a global pandemic in just a few weeks. The number of cancer screening and diagnostic procedures declined precipitously, with countries worldwide affected by the pandemic. An initial analysis of the US market shows that newly diagnosed metastatic non-small-cell lung cancer patient volumes have declined just over 30% from February 2020 to March 2020—this represents a major decline in just one month. This also impacted rate of surgeries that benefit certain patients.

Surgical Instruments segment accounted for the largest share of the lung cancer surgery market, by Surgical Devices, in 2020
Based on devices, the lung cancer surgery market is segmented into surgical instruments, monitoring & visualizing, and endosurgical equipment. In 2020, the surgical instruments segment accounted for the largest market share. The rising prevalence & incidence of lung cancer, rising government support and funding, and the increasing adoption of surgical procedures for lung cancer treatment are the factors driving the market growth.

Thoracotomy segment accounted for the largest share in the market, by Surgical Procedures, in 2020
Based on procedures, the lung cancer surgery market is segmented into thoracotomy and minimally invasive surgeries. In 2020, the thoracotomy segment accounted for the larger share of the lung cancer surgery market. However, the minimally invasive surgeries segment is expected to grow at the highest during the forecast period. The growing adoption of minimally invasive techniques, increasing technological advancements, availability of reimbursement policies, and the increasing trend of robotic surgeries are the factors driving the growth of this market segment.

North America is the largest regional market for lung cancer surgery market
In 2020, North America accounted for the largest market share. The large share of North America can be attributed to rising technological advancements in lung cancer treatment, increasing incidence and prevalence of lung cancer, rising trend of smoking tobacco, increasing emphasis on early diagnosis & treatment of cancers, and the availability of reimbursement.

Some key players in the lung cancer surgery market (2021 - 2026)
Ethicon Inc. (US)
Medtronic Plc. (Ireland)
Olympus Corporation (Japan)